2. Search Result
Search Result
Results for "

headaches

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

1

Peptides

1

Inhibitory Antibodies

5

Natural
Products

10

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19849
    BGC-20-1531 free base

    PGN 1531 free base

    		 Prostaglandin Receptor Neurological Disease
    BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP4 receptor antagonist, with a pKB of 7.6. BGC-20-1531 free base has the potential for the research of migraine headache .
    BGC-20-1531 free base
  • HY-P99021
    Galcanezumab

    LY 2951742

    		 CGRP Receptor Neurological Disease
    Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .
    Galcanezumab
  • HY-B0804
    Nadolol
    1 Publications Verification

    SQ-11725

    		 Adrenergic Receptor Cardiovascular Disease
    Nadolol (SQ-11725) is a non-selective and orally active β-adrenergic receptors blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the the potential for high blood pressure, angina pectoris and vascular headaches research .
    Nadolol
  • HY-101202
    SNC80

    NIH 10815

    		 Opioid Receptor Neurological Disease
    SNC80 (NIH 10815) is a potent, highly selective and non-peptide δ-opioid receptor agonist with a Ki of 1.78 nM and an IC50 of 2.73 nM. SNC80 also selectively activates μ-δ heteromer in HEK293 cells with an EC50 of 52.8 nM. SNC80 shows antinociceptive, antihyperalgesic and antidepressant‐like effects. SNC80 has the potential for multiple headache disorders treatment .
    SNC80
  • HY-B0121B
    Sumatriptan
    3 Publications Verification

    GR 43175 free base

    		 5-HT Receptor Neurological Disease
    Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan can be used for migraine headache research .
    Sumatriptan
  • HY-106736
    Etilefrine pivalate hydrochloride

    		Others Neurological Disease
    Etilefrine pivalate hydrochloride is an orally active compound and can be used for study of migraine headaches .
    Etilefrine pivalate hydrochloride
  • HY-110351
    BGC-20-1531 hydrochloride

    PGN 1531 hydrochloride

    		 Prostaglandin Receptor Neurological Disease
    BGC 20-1531 (PGN 1531) hydrochloride is a potent and selective prostanoid EP4 receptor antagonist, with a pKb of 7.6. BGC 20-1531 hydrochloride has the potential for the research of migraine headache .
    BGC-20-1531 hydrochloride
  • HY-123442
    L 775,606

    		5-HT Receptor Neurological Disease
    L 775,606 is a potent and selective 5-HT1D receptor agonist. L 775,606 can be used to study migraine headache .
    L 775,606
  • HY-N12081
    Oxyresveratrol 4-O-β-D-glucopyranoside

    		Biochemical Assay Reagents Metabolic Disease Inflammation/Immunology
    Oxyresveratrol 4-O-β-D-glucopyranoside (compound 3) is a natural product that can be obtained from the root bark of Morus atropurpurea. Oxyresveratrol 4-O-β-D-glucopyranoside has potential in studies of diabetes, arthritis, rheumatism, cough and headache .
    Oxyresveratrol 4-O-β-D-glucopyranoside
  • HY-B0804R
    Nadolol (Standard)

    		Adrenergic Receptor Cardiovascular Disease
    Nadolol (Standard) is the analytical standard of Nadolol. This product is intended for research and analytical applications. Nadolol (SQ-11725) is a non-selective and orally active β-adrenergic receptors blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the the potential for high blood pressure, angina pectoris and vascular headaches research .
    Nadolol (Standard)
  • HY-B0121A
    Sumatriptan hydrochloride

    GR 43175 hydrochloride

    		 5-HT Receptor Neurological Disease
    Sumatriptan hydrochloride (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan hydrochloride can be used for migraine headache research .
    Sumatriptan hydrochloride
  • HY-B0121
    Sumatriptan succinate
    3 Publications Verification

    GR 43175 succinate

    		 5-HT Receptor Neurological Disease
    Sumatriptan succinate (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan succinate can be used for migraine headache research .
    Sumatriptan succinate
  • HY-B0121R
    Sumatriptan succinate (Standard)

    GR 43175 succinate (Standard)

    		 5-HT Receptor Neurological Disease
    Sumatriptan (succinate) (Standard) is the analytical standard of Sumatriptan (succinate). This product is intended for research and analytical applications. Sumatriptan succinate (GR 43175) is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for migraine headache research .
    Sumatriptan succinate (Standard)
  • HY-B0121BS2
    Sumatriptan-d5

    GR 43175 free base-d5

    		 5-HT Receptor Isotope-Labeled Compounds Neurological Disease
    Sumatriptan-d5 is deuterated labeled Sumatriptan (HY-B0121B). Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan can be used for migraine headache research .
    Sumatriptan-d5
  • HY-W050162
    (E)-3,4,5-Trimethoxycinnamic acid

    TMCA

    		 GABA Receptor 5-HT Receptor Neurological Disease
    (E)-3,4,5-Trimethoxycinnamic acid (TMCA) is a cinnamic acid substituted by multi-methoxy groups. (E)-3,4,5-Trimethoxycinnamic acid is an orally active and potent GABAA/BZ receptor agonist. (E)-3,4,5-Trimethoxycinnamic exhibits favourable binding affinity to 5-HT2C and 5-HT1A receptor, with IC50 values of 2.5 and 7.6 μM, respectively. (E)-3,4,5-Trimethoxycinnamic acid shows anticonvulsant and sedative activity. (E)-3,4,5-Trimethoxycinnamic acid can be used for the research of insomnia, headache and epilepsy .
    (E)-3,4,5-Trimethoxycinnamic acid
  • HY-B0206S
    Rizatriptan-d6 benzoate

    		Isotope-Labeled Compounds 5-HT Receptor Neurological Disease
    Rizatriptan-d6 (benzoate) is the deuterium labeled Rizatriptan benzoate. Rizatriptan benzoate is a 5-HT1 agonist triptan agent for the treatment of migraine headaches[1][2].
    Rizatriptan-d6 benzoate
  • HY-156533A
    5-HT2 agonist-1 free base

    		5-HT Receptor Neurological Disease Inflammation/Immunology Cancer
    5-HT2 agonist-1 (Compound 24) free base is a 5-HT2A & 5-HT2B & 5-HT2C agonist, with IC50s of 10 nM, 8.3, and 1.6 nM respectively. 5-HT2 agonist-1 free base can be used for research of depression, alcoholism, tobacco and cocaine addiction, inflammation, cluster headache, PTSD, seizure disorders and other CNS disorders .
    5-HT2 agonist-1 free base
  • HY-156533
    5-HT2 agonist-1

    		5-HT Receptor Cancer
    5-HT2 agonist-1 (Compound 24) is a 5-HT2A & 5-HT2B & 5-HT2C agonist, with IC50s of 10 nM, 8.3, and 1.6 nM respectively. 5-HT2 agonist-1 free base can be used for research of depression, alcoholism, tobacco and cocaine addiction, inflammation, cluster headache, PTSD, seizure disorders and other CNS disorders .
    5-HT2 agonist-1
  • HY-156534
    5-HT2A&5-HT2C agonist-1

    		5-HT Receptor Neurological Disease Inflammation/Immunology Cancer
    5-HT2A&5-HT2C agonist-1 (Example 2) is a 5-HT2A & 5-HT2C agonist, with IC50s of 196 nM and 0.9 nM respectively. 5-HT2A&5-HT2C agonist-1 can be used for research of depression, alcoholism, tobacco and cocaine addiction, inflammation, cluster headache, PTSD, seizure disorders and other CNS disorders .
    5-HT2A&5-HT2C agonist-1
  • HY-10585
    Valproic acid
    Maximum Cited Publications
    41 Publications Verification

    Dipropylacetic Acid

    		 Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite Infection Neurological Disease Metabolic Disease Cancer
    Valproic acid (VPA) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM. Valproic acid inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .
    Valproic acid
  • HY-101635
    Proxibarbal

    Proxibarbital

    		 5-HT Receptor Histamine Receptor Neurological Disease
    Proxibarbal is a barbiturate derivative. It has anti-anxiety properties and is also used in the treatment of migraine headaches.
    Proxibarbal
  • HY-10585A
    Valproic acid sodium
    Maximum Cited Publications
    41 Publications Verification

    Sodium Valproate sodium

    		 Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite Infection Neurological Disease Metabolic Disease Cancer
    Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .
    Valproic acid sodium
  • HY-10585B
    Valproic acid (sodium)(2:1)

    VPA (sodium)(2:1); 2-Propylpentanoic Acid (sodium)(2:1)

    		 HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite Infection Neurological Disease Metabolic Disease Cancer
    Valproic acid (VPA) sodium (2:1) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium (2:1) activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .
    Valproic acid (sodium)(2:1)
  • HY-10585AR
    Valproic acid sodium (Standard)

    		Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite Infection Neurological Disease Metabolic Disease Cancer
    Valproic acid (sodium) (Standard) is the analytical standard of Valproic acid (sodium). This product is intended for research and analytical applications. Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .
    Valproic acid sodium (Standard)
  • HY-B0197
    Naratriptan

    GR-85548A

    		 5-HT Receptor Neurological Disease
    Naratriptan is a selective 5-HT1 receptor subtype agonist and is a triptan drug that is used for the treatment of migraine headaches.
    Naratriptan
  • HY-B0197A
    Naratriptan hydrochloride
    2 Publications Verification

    GR-85548A hydrochloride

    		 5-HT Receptor Neurological Disease
    Naratriptan hydrochloride is a selective 5-HT1 receptor subtype agonist and is a triptan drug that is used for the treatment of migraine headaches.
    Naratriptan hydrochloride
  • HY-10585G
    Valproic acid

    Dipropylacetic acid

    		 Organoid HDAC Autophagy Mitochondrial Metabolism HIV Notch Apoptosis Endogenous Metabolite Infection Neurological Disease Metabolic Disease Cancer
    Valproic acid (GMP) is Valproic acid (HY-10585) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Valproic acid (VPA) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM. Valproic acid inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .
    Valproic acid
  • HY-10585AS
    Valproic acid-d7 sodium

    Sodium Valproate-d7(sodium)

    		 Isotope-Labeled Compounds HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite Cancer
    Valproic acid-d7 (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].
    Valproic acid-d7 sodium
  • HY-110029
    Paroxetine maleate

    BRL29060 maleate

    		 Serotonin Transporter Neurological Disease
    Paroxetine maleate is a potent and selective inhibitor of SSRI. Paroxetine maleate is used in generalized anxiety disorder, post traumatic stress disorder, premenstrual dysphoric disorder and chronic headache research .
    Paroxetine maleate
  • HY-10585S4
    Valproic acid-d4-1

    VPA-d4-1; 2-Propylpentanoic Acid-d4-1

    		 Isotope-Labeled Compounds HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite Cancer
    Valproic acid-d4-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].
    Valproic acid-d4-1
  • HY-10585S2
    Valproic acid-d15

    VPA-d15; 2-Propylpentanoic Acid-d15

    		 HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite Cancer
    Valproic acid-d15 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].
    Valproic acid-d15
  • HY-10585S
    Valproic acid-d4

    VPA-d4; 2-Propylpentanoic Acid-d4

    		 HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite Cancer
    Valproic acid-d4 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].
    Valproic acid-d4
  • HY-B1658
    Frovatriptan

    (R)-Frovatriptan; SB 209509; VML 251

    		 5-HT Receptor Neurological Disease
    Frovatriptan is a potent 5-HT1B//D receptor agonist and has the highest 5-HT1B potency in the triptan class. Frovatriptan is apparently cerebroselective. Frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura .
    Frovatriptan
  • HY-10585AS1
    Valproic acid-d14 sodium

    Sodium Valproate-d14 sodium

    		 Isotope-Labeled Compounds HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite Cancer
    Valproic acid-d14 (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
    Valproic acid-d14 sodium
  • HY-101202A
    (Rac)-SNC80

    (Rac)-NIH 10815

    		 Opioid Receptor Neurological Disease
    (Rac)-SNC80 is a racemate of SNC80 (HY-101202). SNC80 (NIH 10815) is a potent, highly selective and non-peptide δ-opioid receptor agonist with a Ki of 1.78 nM and an IC50 of 2.73 nM. SNC80 shows antinociceptive, antihyperalgesic and antidepressant‐like effects. SNC80 has the potential for multiple headache disorders treatment .
    (Rac)-SNC80
  • HY-B1658S
    Frovatriptan-d3 hydrochloride

    (R)-Frovatriptan-d3 hydrochloride; SB 209509-d3 hydrochloride; VML 251-d3 hydrochloride

    		 5-HT Receptor Neurological Disease
    Frovatriptan-d3 (hydrochloride) is the deuterium labeled Frovatriptan[1]. Frovatriptan is a potent 5-HT1B//D receptor agonist and has the highest 5-HT1B potency in the triptan class. Frovatriptan is apparently cerebroselective. Frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura[2].
    Frovatriptan-d3 hydrochloride
  • HY-10585S3
    Valproic acid-d4 sodium

    VPA-d4 sodium; 2-Propylpentanoic Acid-d4 sodium

    		 Isotope-Labeled Compounds HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite Cancer
    Valproic acid-d4 (sodium) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
    Valproic acid-d4 sodium
  • HY-B0121BS
    Sumatriptan-d6 succinate

    GR 43175C-d6

    		 5-HT Receptor Isotope-Labeled Compounds Neurological Disease
    Sumatriptan-d6 succinate is the deuterium labeled Sumatriptan succinate. Sumatriptan succinate is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for migraine headache research .
    Sumatriptan-d6 succinate
  • HY-122272
    Paroxetine
    5+ Cited Publications

    BRL29060

    		 Serotonin Transporter Adrenergic Receptor P2X Receptor Apoptosis Neurological Disease Cancer
    Paroxetine is an oral inhibitor that falls under the category of selective serotonin reuptake inhibitors (SSRIs). Paroxetine is also a very weak norepinephrine (NE) reuptake inhibitor, capable of inducing cell apoptosis and having anti-tumor activity. Paroxetine has antidepressant, anti-anxiety, and pain-relieving effects, and it can help improve conditions like obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual anxiety, and chronic headaches .
    Paroxetine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: